A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design

References

• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548 - 58; http://dx.doi.org/10.1038/clpt.2008.170; PMID: 18784655
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413 - 5; http://dx.doi.org/10.4161/mabs.19931; PMID: 22531442
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645 - 68; http://dx.doi.org/10.1002/jps.20178; PMID: 15389672
   PubMed Web of Science ®Google Scholar
• Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10:84 - 96; PMID: 17265746
   PubMed Web of Science ®Google Scholar
• Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966; 2:1087 - 93; http://dx.doi.org/10.1016/S0140-6736(66)92190-8; PMID: 4162525
   PubMed Web of Science ®Google Scholar
• Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 2012; 14:296 - 302; http://dx.doi.org/10.1208/s12248-012-9340-y; PMID: 22407289
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633 - 59; http://dx.doi.org/10.2165/11535960-000000000-00000; PMID: 20818831
   PubMed Web of Science ®Google Scholar
• Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49:1012 - 24; http://dx.doi.org/10.1177/0091270009337512; PMID: 19620385
   PubMed Web of Science ®Google Scholar
• Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012; 51:119 - 35; http://dx.doi.org/10.2165/11596370-000000000-00000; PMID: 22257150
   PubMed Web of Science ®Google Scholar
• D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9:739 - 56; http://dx.doi.org/10.1007/BF01070904; PMID: 7341758
   PubMedGoogle Scholar
• Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 2012; 51:247 - 60; http://dx.doi.org/10.2165/11598090-000000000-00000; PMID: 22420579
   PubMedGoogle Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50:131 - 42; http://dx.doi.org/10.2165/11537430-000000000-00000; PMID: 21241072
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?. MAbs 2011; 3:61 - 6; http://dx.doi.org/10.4161/mabs.3.1.13799; PMID: 20962582
   PubMed Web of Science ®Google Scholar
• Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49:1382 - 402; http://dx.doi.org/10.1177/0091270009337134; PMID: 19837907
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 2012; 14:554 - 8; http://dx.doi.org/10.1208/s12248-012-9369-y; PMID: 22610647
   PubMed Web of Science ®Google Scholar
• Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287:11090 - 7; http://dx.doi.org/10.1074/jbc.M111.319764; PMID: 22294692
   PubMed Web of Science ®Google Scholar
• Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 2008; 8:401 - 13; http://dx.doi.org/10.1016/j.intimp.2007.10.023; PMID: 18279794
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Wu AM, DiStefano JJ 3rd. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 2005; 33:1640 - 52; http://dx.doi.org/10.1007/s10439-005-7410-3; PMID: 16341929
   PubMed Web of Science ®Google Scholar
• Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 2008; 35:101 - 16; http://dx.doi.org/10.1007/s10928-007-9078-9; PMID: 17963024
   PubMed Web of Science ®Google Scholar
• Gastonguay MR. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies, abstr 2229. Abstr Annu Meet Popul Approach Group Eur 2011; 20:http://www.page-meeting.org/?abstr=2229.
   Google Scholar
• Larsen RJ, Marx ML. An Introduction to Mathematical Statistics. Upper Saddle River, NJ: Prentice-Hall, 1986.
   Google Scholar
• Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001; 18:83 - 9; http://dx.doi.org/10.1023/A:1011035028755; PMID: 11336357
   PubMed Web of Science ®Google Scholar
• Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed 2002; 69:25 - 35; http://dx.doi.org/10.1016/S0169-2607(01)00178-X; PMID: 12088590
   PubMed Web of Science ®Google Scholar
• Hooker AC, Foracchia M, Dodds MG, Vicini P. An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng 2003; 31:98 - 111; http://dx.doi.org/10.1114/1.1533074; PMID: 12572660
   PubMed Web of Science ®Google Scholar